| (Values in U.S. Thousands) | Jun, 2019 | Mar, 2019 | Dec, 2018 | Sep, 2018 | Jun, 2018 |
| Sales | 0 | 0 | 0 | 0 | 25,000 |
| Sales Growth | unch | unch | unch | -100.00% | unch |
| Net Income | 0 | -2,210 | -4,890 | -14,990 | 2,920 |
| Net Income Growth | +100.00% | +54.81% | +67.38% | -613.36% | +119.97% |
Aquinox Pharmaceutic (AQXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.